The DEA is launching its second attempt to classify five obscure psychedelic compounds as Schedule I illegal drugs, directly clashing with the FDA’s ongoing efforts to legitimize them. While the DEA cites decades-old, non-lethal poison control data to justify a total ban, the FDA recently granted "breakthrough therapy" status to one of these exact substances as a promising … [Read more...] about The DEA is Trying to Arrest Your Future Antidepressants
FDA
The Dog Ate My Homework, and the FDA Lost Its Cannabinoid List
Congress gave the Food and Drug Administration a single ninety-day assignment, and half a year after the deadline sailed by, the agency still hasn't turned in its paper. According to a fresh report from the Congressional Research Service, the FDA is now six months late in publishing mandatory guidance on hemp cannabinoids and packaging definitions—leaving an entire … [Read more...] about The Dog Ate My Homework, and the FDA Lost Its Cannabinoid List
Think Twice Before You Post
The next time you’re settling into your couch to debate the nuances of terpene profiles on Reddit, film a glossy CBD haul for TikTok, or tell your Instagram followers that a particular gummy cured your existential dread, remember to smile for the feds. The Food and Drug Administration is currently out shopping for a private contractor to help them scroll through your weed … [Read more...] about Think Twice Before You Post
The Waiting Game: Is Federal Rescheduling the Fix Connecticut’s Cannabis Market Needs?
For Connecticut’s cannabis entrepreneurs, the buzz surrounding the potential federal move to reclassify marijuana from Schedule I to Schedule III is palpable. It is being hailed as a historic milestone, but if you talk to those on the ground—the business owners, policy experts, and dispensary managers—the mood is less of a victory lap and more of a cautious "wait and see." … [Read more...] about The Waiting Game: Is Federal Rescheduling the Fix Connecticut’s Cannabis Market Needs?
Feds Eye Cannabis Crackdown—Not for the Weed, but the Wild Claims
A powerful House committee is turning up the heat on the cannabis industry—this time over what companies are saying, not just what they’re selling. In a newly approved spending bill report, lawmakers are urging federal regulators—especially the FDA—to crack down on cannabis product manufacturers that make unproven or misleading health claims. The concern? A flood of … [Read more...] about Feds Eye Cannabis Crackdown—Not for the Weed, but the Wild Claims
FDA Memo Paves Way for CBD to Be Covered by Medicare
A recent enforcement memo from the U.S. Food and Drug Administration (FDA) signals that the agency will not block a new federal initiative allowing certain hemp-derived cannabidiol (CBD) products to be covered under a Medicare plan — a major change in how these products are treated at the federal level.Under the memo, eligible Medicare patients may be able to receive up to $500 … [Read more...] about FDA Memo Paves Way for CBD to Be Covered by Medicare
The CBD Party’s Ending—FDA Just Flipped the Lights On
For years, CBD has been living its best life in a regulatory gray zone—sold everywhere, claimed to do everything, and barely bothered by the people in charge. That era might be coming to an end.The FDA just made a quiet but meaningful move, sending a new CBD compliance and enforcement policy to the White House for review. It’s not a full-blown rulebook yet, but it’s the … [Read more...] about The CBD Party’s Ending—FDA Just Flipped the Lights On
FDA Chief Acknowledges Medical Benefits Of Cannabis While Warning Of Risks
The head of the U.S. Food and Drug Administration says marijuana may offer meaningful therapeutic value for certain patients, even as federal officials continue to raise concerns about potential health risks — particularly among young users.During a recent television interview, FDA Commissioner Marty Makary emphasized that the administration is balancing two priorities: … [Read more...] about FDA Chief Acknowledges Medical Benefits Of Cannabis While Warning Of Risks
Trump’s Hemp Headache: FDA Scrambles to Finish the Rules He Signed
The FDA is racing a deadline tied to a law Donald Trump signed, and the hemp industry is watching closely. The agency has to publish official lists of cannabinoids and explain what counts as a hemp product “container”—details that could decide what products stay legal.This all traces back to the spending law Trump signed in late 2025, which rewrites the federal definition of … [Read more...] about Trump’s Hemp Headache: FDA Scrambles to Finish the Rules He Signed
MMJ’s FDA-First Cannabis Pharmaceutical Model Thrives Amid DEA Regulatory Gridlock
While the U.S. cannabis industry grapples with regulatory stagnation, companies are diverging in their responses to the political gridlock. Green Thumb Industries CEO Ben Kovler recently voiced frustration over federal inertia, criticizing agencies like the DEA as "out of touch" and resistant to reform. Yet, amid this uncertainty, MMJ International Holdings has charted a … [Read more...] about MMJ’s FDA-First Cannabis Pharmaceutical Model Thrives Amid DEA Regulatory Gridlock
